Research Reveals How Fructose in Diet Enhances Tumor Growth

Fructose consumption has increased considerably over the past five decades, largely due to the widespread use of high-fructose corn syrup as a sweetener in beverages and ultra-processed foods. New research from Washington University in St. Louis shows that dietary fructose promotes tumor growth in animal models of melanoma, breast cancer and cervical cancer. However, fructose does not directly fuel tumors, according to the study published Dec. 4 in the journal Nature.

Instead, Washington University scientists discovered that the liver converts fructose into usable nutrients for cancer cells, a compelling finding that could open up new avenues for care and treatment of many different types of cancer.

Gary Patti, PhD
Gary Patti, PhD

“The idea that you can tackle cancer with diet is intriguing,” said Gary Patti, PhD, the Michael and Tana Powell Professor of Chemistry in Arts & Sciences and a professor of genetics and of medicine at the School of Medicine, all at Washington University. Patti also is a research member of Siteman Cancer Center, based at Barnes-Jewish Hospital and the School of Medicine.

“When we think about tumors, we tend to focus on what dietary components they consume directly. You put something in your body, and then you imagine that the tumor takes it up,” Patti said. “But humans are complex. What you put in your body can be consumed by healthy tissue and then converted into something else that tumors use.”

Ronald Fowle Grider
Ronald Fowle-Grider, PhD

“Our initial expectation was that tumor cells metabolize fructose just like glucose, directly utilizing its atoms to build new cellular components such as DNA. We were surprised that fructose was barely metabolized in the tumor types we tested,” said the study’s first author, Ronald Fowle-Grider, PhD, a postdoctoral fellow in Patti’s lab. “We quickly learned that the tumor cells alone don’t tell the whole story. Equally important is the liver, which transforms fructose into nutrients that the tumors can use.”

Using metabolomics — a method of profiling small molecules as they move through cells and across different tissues in the body — the researchers concluded that one way in which high levels of fructose consumption promote tumor growth is by increasing the availability of circulating lipids in the blood. These lipids are building blocks for the cell membrane, and cancer cells need them to grow.

“We looked at numerous different cancers in various tissues throughout the body, and they all followed the same mechanism,” Patti said.

The Corn Syrup Era

Scientists have long recognized that cancer cells have a strong affinity for glucose, a simple sugar that is the body’s preferred carbohydrate-based energy source.

In terms of its chemical structure, fructose is similar to glucose. They are both common types of sugar, with the same chemical formula, but they differ in how the body metabolizes them. Glucose is processed throughout the whole body, while fructose is almost entirely metabolized by the small intestine and liver.

Both sugars are found naturally in fruits, vegetables, dairy products and grains. They are also added as sweeteners in many processed foods. Fructose, in particular, has penetrated the American diet over the last few decades. It is favored by the food industry because it is sweeter than glucose.

Prior to the 1960s, people consumed relatively little fructose compared with today’s numbers. A century ago, an average person consumed just 5-10 pounds of fructose per year. To put it in familiar terms, that is roughly equal to the weight of a gallon of milk. In the 21st century, that number has increased to be as high as the equivalent of 15 gallons of milk.

“If you go through your pantry and look for the items that contain high-fructose corn syrup, which is the most common form of fructose, it is pretty astonishing,” said Patti, who also is a research member of the Center for Human Nutrition at the School of Medicine. “Almost everything has it. It’s not just candy and cake, but also foods such as pasta sauce, salad dressing and ketchup,” he said. “Unless you actively seek to avoid it, it’s probably part of your diet.”

Cancer’s Appetite for Fructose

Given the rapid rise in the consumption of dietary fructose over recent decades, the Washington University researchers wanted to know more about how fructose impacts the growth of tumors.

Patti and Fowle-Grider began their investigation by feeding tumor-bearing animals a diet rich in fructose, then measuring how quickly their tumors grew. The researchers found that added fructose promoted tumor growth without changing body weight, fasting glucose or fasting insulin levels.

“We were surprised to see that it had a rather dramatic impact. In some cases, the growth rate of the tumors accelerated by two-fold or even higher,” Patti said. “Eating a lot of fructose was clearly very bad for the progression of these tumors.”

But the next step in their experiments initially stumped them. When Fowle-Grider attempted to repeat a version of this test by feeding fructose to cancer cells isolated in a dish, the cells did not respond. “In most cases they grew almost as slowly as if we gave them no sugar at all,” Patti said.

So, Patti and Fowle-Grider went back to looking at changes in the small molecules in the blood of animals fed high-fructose diets. Using metabolomics, they identified elevated levels of a variety of lipid species, including lysophosphatidylcholines (LPCs). Additional dish tests showed that liver cells that were fed fructose release LPCs.

“Interestingly, the cancer cells themselves were unable to use fructose readily as a nutrient because they do not express the right biochemical machinery,” Patti said. “Liver cells do. This allows them to convert fructose into LPCs, which they can secrete to feed tumors.”

A defining characteristic of cancer is uncontrolled proliferation of malignant cells. Each time a cell divides, it must replicate its contents, including membranes. This requires a substantial amount of lipids. While lipids can be synthesized from scratch, it is much easier for cancer cells to simply take lipids up from their surrounding environment.

“Over the past few years, it’s become clear that many cancer cells prefer to take up lipids rather than make them,” Patti noted. “The complication is that most lipids are insoluble in blood and require rather complex transport mechanisms. LPCs are unique. They might provide the most effective and efficient way to support tumor growth.”

Avoiding Fructose

Interestingly, over the same period of time when human fructose consumption has surged, a number of cancers have become increasingly more prevalent among people under the age of 50. This raises the question of whether the trends are linked. With $25 million in support from Cancer Grand Challenges, Patti recently teamed up with Yin Cao, ScD, MPH, an associate professor of surgery at the School of Medicine and a fellow Siteman research member, and other investigators from around the world, none of whom were involved in this study, to investigate possible connections.

“It will be exciting to better understand how dietary fructose influences cancer incidence. But one take-home message from this current study is that if you are unfortunate enough to have cancer, then you probably want to think about avoiding fructose. Sadly, that is easier said than done,” Patti said.

Aside from dietary intervention, the study authors said that this research could help us develop a way to prevent fructose from driving tumor growth therapeutically, using drugs.

“An implication of these findings is that we do not have to limit ourselves to therapeutics that only target disease cells,” Patti said. “Rather, we can think about targeting the metabolism of healthy cells to treat cancer. This has worked with mice in our study, but we would like to take advantage of our observations and try to improve the lives of patients.”

The study authors are working with clinical partners at Washington University School of Medicine to explore a clinical trial related to fructose in the diet.

Analyzing multiple mammograms improves breast cancer risk prediction

AI method spots subtle changes over time, enhances accuracy of determining 5-year risk

A new study from Washington University School of Medicine in St. Louis describes an innovative method of analyzing mammograms that significantly improves the accuracy of predicting the risk of breast cancer development over the following five years. Using up to three years of previous mammograms, the new method identified individuals at high risk of developing breast cancer 2.3 times more accurately than the standard method, which is based on questionnaires assessing clinical risk factors alone, such as age, race and family history of breast cancer.

The study is published Dec. 5 in JCO Clinical Cancer Informatics.

“We are seeking ways to improve early detection, since that increases the chances of successful treatment,” said senior author Graham A. Colditz, MD, DrPH, associate director, prevention and control, of Siteman Cancer Center, based at Barnes-Jewish Hospital and the School of Medicine, and the Niess-Gain Professor of Surgery. “This improved prediction of risk also may help research surrounding prevention, so that we can find better ways for women who fall into the high-risk category to lower their five-year risk of developing breast cancer.”

This risk-prediction method builds on past research led by Colditz and lead author Shu (Joy) Jiang, PhD, a statistician, data scientist and associate professor of surgery in the Division of Public Health Sciences at the School of Medicine. The researchers showed that prior mammograms hold a wealth of information on early signs of breast cancer development that can’t be perceived even by a well-trained human eye. This information includes subtle changes over time in breast density, which is a measure of the relative amounts of fibrous versus fatty tissue in the breasts.

For the new study, the team built an algorithm based on artificial intelligence that can discern subtle differences in mammograms and help identify those women at highest risk of developing a new breast tumor over a specific timeframe. In addition to breast density, their machine-learning tool considers changes in other patterns in the images, including in texture, calcification and asymmetry within the breasts.

“Our new method is able to detect subtle changes over time in repeated mammogram images that are not visible to the eye,” said Jiang, yet these changes hold rich information that can help identify high-risk individuals.

At the moment, risk-reduction options are limited and can include drugs such as tamoxifen that lower risk but may have unwanted side effects. Most of the time, women at high risk are offered more frequent screening or the option of adding another imaging method, such as an MRI, to try to identify cancer as early as possible.

“Today, we don’t have a way to know who is likely to develop breast cancer in the future based on their mammogram images,” said co-author Debbie L. Bennett, MD, an associate professor of radiology and chief of breast imaging for the Mallinckrodt Institute of Radiology at the School of Medicine. “What’s so exciting about this research is that it indicates that it is possible to glean this information from current and prior mammograms using this algorithm. The prediction is never going to be perfect, but this study suggests the new algorithm is much better than our current methods.”

AI Improves Prediction of Breast Cancer Development

The researchers trained their machine-learning algorithm on the mammograms of more than 10,000 women who received breast cancer screenings through Siteman Cancer Center from 2008 – 2012. These individuals were followed through 2020, and in that time 478 were diagnosed with breast cancer.

The researchers then applied their method to predict breast cancer risk in a separate set of patients — more than 18,000 women who received mammograms through Emory University in the Atlanta area from 2013 – 2020. Subsequently, 332 women were diagnosed with breast cancer during the follow-up period, which ended in 2020.

According to the new prediction model, women in the high-risk group were 21 times more likely to be diagnosed with breast cancer over the following five years than were those in the lowest-risk group. In the high-risk group, 53 out of every 1,000 women screened developed breast cancer over the next five years. In contrast, in the low-risk group, 2.6 women per 1,000 screened developed breast cancer over the following five years. Under the old questionnaire-based methods, only 23 women per 1,000 screened were correctly classified in the high-risk group, providing evidence that the old method, in this case, missed 30 breast cancer cases that the new method found.

The mammograms were conducted at academic medical centers and community clinics, demonstrating that the accuracy of the method holds up in diverse settings. Importantly, the algorithm was built with robust representation of Black women, who are usually underrepresented in development of breast cancer risk models. The accuracy for predicting risk held up across racial groups. Of the women screened through Siteman, most were white, and 27% were Black. Of those screened through Emory, 42% were Black.

In ongoing work, the researchers are testing the algorithm in women of diverse racial and ethnic backgrounds, including those of Asian, southeast Asian and Native American descent, to help ensure that the method is equally accurate for everyone.

The researchers are working with Washington University’s Office of Technology Management toward patents and licensing on the new method with the goal of making it broadly available anywhere screening mammograms are provided. Colditz and Jiang also are working toward founding a start-up company around this technology.

Vaccine Shows Promise Against Aggressive Breast Cancer

Clinical trial targeted recurrence of hard-to-treat triple-negative breast cancer

A small clinical trial shows promising results for patients with triple-negative breast cancer who received an investigational vaccine designed to prevent recurrence of tumors. Conducted at Washington University School of Medicine in St. Louis with a therapy designed by Washington University researchers, the trial is the first to report results for this type of vaccine — known as a neoantigen DNA vaccine — for breast cancer patients.

The study, which found the vaccine to be well-tolerated and to stimulate the immune system, is available Nov. 14 in the journal Genome Medicine.

The phase I clinical trial — conducted at Siteman Cancer Center, based at Barnes-Jewish Hospital and the School of Medicine — involved 18 patients diagnosed with triple-negative breast cancer that was not metastatic, meaning it had not spread to other organs. Each patient received the standard of care and three doses of a personalized vaccine tailored to home in on key mutations in their specific tumor and train immune cells to recognize and attack any cells bearing these mutations.

Following treatment, 14 of 18 patients showed immune responses to the vaccine and, after three years, 16 patients remained cancer-free. While the early-stage trial was designed to evaluate safety of the vaccine and did not include a control group to determine efficacy, the researchers analyzed historical data from patients with triple-negative breast cancer treated with the standard of care only. In that group, on average, about half of patients remained cancer-free at three years post-treatment.

“These results were better than we expected,” said senior author William E. Gillanders, MD, the Mary Culver Distinguished Professor of Surgery at the School of Medicine who treats patients at Siteman. “Obviously, it’s not a perfect comparison, and we acknowledge the limitations of this type of analysis, but we are continuing to pursue this vaccine strategy and have ongoing randomized controlled trials that do make a direct comparison between the standard of care plus a vaccine, versus standard of care alone. We are encouraged by what we’re seeing with these patients so far.”

Triple-negative breast cancer is an aggressive tumor type that grows even in the absence of the hormonal fuel that drives growth of other types of breast cancer. To date, triple-negative breast cancer has no targeted therapies and is usually treated with traditional approaches that include surgery, chemotherapy and radiation therapy. For reasons that scientists are still investigating, this tumor tends to be more common among African American patients diagnosed with breast cancer. In this trial, one-third of the participants (six of 18) were African American.

For this trial, patients with triple-negative breast cancer who still had evidence of a tumor remaining after a first round of chemotherapy were eligible to participate. Such patients are at high risk of cancer recurrence even after the remaining tumor is surgically removed. After surgical removal, the research team analyzed and compared the tumor tissue with the same patient’s healthy tissue to find unique genetic mutations in the cancer cells. Such mutations in a patient’s cancer cells alter the proteins only in the tumor, making it possible to train the immune system to go after the altered proteins and leave healthy tissues alone.

Using software they designed, the researchers selected altered proteins — called neoantigens — that were made by the patients’ tumors and that were identified as most likely to trigger a strong immune response. On average, each patient’s vaccine contained 11 neoantigens (ranging from a minimum of four to a maximum of 20) specific to their tumor.

The software development was led by computational biologists Obi Griffith, PhD, a professor of medicine, and Malachi Griffith, PhD, an associate professor of medicine, both in the Division of Oncology at the School of Medicine. A related paper published simultaneously in the same journal describes the software tools they developed. One of their goals is to make these computational resources widely accessible to cancer researchers and clinicians worldwide.

“We hope to promote the use of this software for the design of cancer vaccines,” Malachi Griffith said. “These are complex algorithms, but in general, the software takes in a list of mutations and interprets them in the context of their potential to be good neoantigen candidates. The tools rank the possible neoantigens based on our current knowledge of what matters in stimulating the immune system to attack cancer cells. These software tools were developed with support from the National Cancer Institute, and they have an open license that makes them broadly available for both academic and commercial uses.”

Several studies of cancer vaccines are ongoing at Siteman. Vaccines for all of these trials are made in a Washington University School of Medicine facility that meets the good manufacturing practice (GMP) requirements set by the Food and Drug Administration. In some of the vaccine clinical trials for breast cancer patients, personalized vaccines are being investigated in combination with immunotherapies called checkpoint inhibitors that boost the action of T cells.

“We are excited about the promise of these neoantigen vaccines,” Gillanders said. “We are hopeful that we will be able to bring more and more of this type of vaccine technology to our patients and help improve treatment outcomes in patients with aggressive cancers.”

Learn more about all breast cancer clinical trials available at Siteman.

________________________________________________________________________________________

Zhang X, Goedegebuure P, Chen MY, Mishra R, Zhang F, Yu YY, Singhal K, Li L, Gao F, Myers NB, Vickery T, Hundal J, McLellan MD, Sturmoski MA, Kim SW, Chen I, Davidson JT, Sankpal NV, Myles S, Suresh R, Ma CX, Foluso A, Wang-Gillam A, Davies S, Hagemann IS, Mardis ER, Griffith O, Griffith M, Miller CA, Hansen TH, Fleming TP, Schreiber RD, Gillanders WE. Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients. Genome Medicine. Nov. 14, 2024.

This work was supported by Susan G. Komen for the Cure, grant number KG111025; the Alvin J. Siteman Cancer Center/Siteman Investment Program grant 4035; the National Institutes of Health (NIH), grant numbers R01 CA240983, P30‐CA091842, U01 CA248235 and T32 CA009621; the Foundation for Barnes‐Jewish Hospital; and the Centene Corporation contract P19‐00559 B101 for the Washington University‐Centene ARCH Personalized Medicine Initiative.

Xia H, Hoang MH, Schmidt E, Kiwala S, McMichael J, Skidmore ZL, Fisk B, Song JJ, Hundal J, Mooney T, Walker JR, Goedegebuure SP, Miller CA, Gillanders WE, Griffith OL, Griffith M. pVACview: an interactive visualization tool for efficient neoantigen prioritization and selection. Genome Medicine. Nov. 14, 2024.

This work was supported by the National Human Genome Research Institute (NHGRI) of the National Institutes of Health (NIH), grant number R00HG007940; the National Cancer Institute (NCI) of the NIH, grant number U01CA248235; the V Foundation for Cancer Research, award number V2018-007; the Centene Corporation contract P19-00559 for the Washington University-Centene ARCH Personalized Medicine Initiative; and the Goldberg Family Foundation.

This content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.

Probiotic delivers anticancer drug to the gut

Oral immunotherapy shrinks gastrointestinal tumors in mouse study

Immunotherapy is a promising treatment that recruits the immune system to help fight cancer, but it has had limited success in gastrointestinal cancers. Now, researchers at Washington University School of Medicine in St. Louis have engineered a probiotic that delivers immunotherapy directly to the gut to shrink tumors in mice, offering a potentially promising oral drug for hard-to-reach cancers.

The probiotic cancer treatment, described Nov. 20 in the journal Cell Chemical Biology, establishes a customizable drug delivery system that can be modified to potentially treat other gut diseases.

“Gastrointestinal cancers are difficult to treat, in part because of their location,” said Gautam Dantas, PhD, the study’s senior author and the Conan Professor of Laboratory and Genomic Medicine in the Department of Pathology & Immunology at WashU Medicine. “We have engineered a yeast-based probiotic that delivers immunotherapy directly to the tumor site. Our hope is that one day the probiotic could be added to the arsenal of therapies to help shrink tumors in people.”

Gastrointestinal cancers, including stomach, liver, esophageal, pancreatic and colorectal cancers, represent more than one-quarter of all cancers. More than 5 million people are living with such cancers – a number that is growing – and 3.7 million die worldwide each year. Late-stage detection, due in part by anatomical challenges that hinder imaging and sampling of the long and complex gastrointestinal system composed of various organs and tissues, has contributed to the high mortality rate. Patients may require a combination therapy regime, including surgery, chemotherapy, radiation therapy and immunotherapy, among others.

Although immunotherapy drugs for gastrointestinal cancers are available, they are delivered intravenously and often exhibit limited effectiveness. Safe doses of immunotherapy may not be sufficient to reach the tumor site and be effective, Dantas explained. Oral immunotherapy drugs could directly target hard-to-reach gastrointestinal cancers, but such protein-based treatments degrade in the gut’s harsh environment before reaching the tumors. Probiotics – bacteria and yeast – can withstand stomach acid and digesting enzymes, offering a potentially promising strategy for safely transporting protein-based drugs that otherwise would get chewed up.

Co-first author Olivia Rebeck, who conducted the experiments when she was a graduate student in the Dantas lab with postdoctoral scholars Miranda Wallace, PhD, and Jerome Prusa, PhD, used a yeast strain to deliver immunotherapy to the gut. The yeast – Saccharomyces cerevisiae var. boulardii – is a commonly used and safe probiotic. Unlike bacteria, the microorganism is less likely to exchange genetic material with other microbes and doesn’t take up residence in the gastrointestinal tract where it could potentially disrupt microbial communities. Its natural anticancer properties, found to inhibit some types of cancer cells in a dish, potentially offer an additional benefit.

The researchers engineered yeast to act as single-celled drug factories and produce immune checkpoint inhibitors – anticancer drugs that alert immune cells to the presence of cancer cells. Tumors sabotage the process that the body’s healthy cells use to avoid immune recognition and subsequent attack, allowing cancer to hide from the immune system. The researchers found the yeast-based probiotic made and secreted the drug that releases the brake on the immune system, allowing it to fight tumors.

The researchers gave mice with colorectal cancer the drug-making probiotic or an intravenous injection of the immunotherapy drug. They found fewer tumors in mice receiving the probiotic compared with mice given immunotherapy drugs systemically.

The researchers have filed two patents – with help from the Office of Technology Management at WashU – related to the engineered probiotic.

Using yeast as a delivery system can be adapted for other gastrointestinal diseases. The researchers are currently working on modifying the system to help combat Clostridioides difficile, commonly referred to as C. diff, a bacterium that can cause diarrhea and colitis, among other symptoms. Delivering therapies that directly target the bug or its toxins could potentially replace the need for antibiotics that also harm beneficial gut microbes.

# # #

Rebeck ON, WallaceMJ, Prusa J, Ning J, Evbuomwan EM, Rengarajan S, Habimana-Griffin L, Kwak S, Zahrah D, Tung J, Liao J, Mahmud B, Fishbein SRS, Ramirez Tovar ES, Mehta R, Wang B, Gorelik MG, Helmink BA, Dantas G. A yeast-based oral therapeutic platform for delivery of immune checkpoint inhibitors reduces intestinal tumor burden. Cell Chemical Biology. Nov 20, 2024.
DOI: 10.1016/j.chembiol.2024.10.013

This study was funded by the National Institute of Allergy and Infectious Diseases of the National Institutes of Health (NIH), grant numbers R01AI155893 and K99AI17674; the National Center for Complementary and Integrative Health of the National Institutes of Health (NIH), grant numbers R01AT00974 and K99AT012651; the National Institute of General Medicine Scientists of the NIH, grant numbers T32GM007067, R25GM103757 and 5T34GM141639; the National Cancer Institute of the NIH, grant number T32CA11327; the National Institute of Child Health and Human Development of the NIH, grant number T32HD004010; the National Institute of Diabetes and Digestive and Kidney Diseases of the NIH, grant number T32DK077653. Radiological Society of North America, grant number RR2336; the Washington University/Mallinckrodt/Siteman Kornfeld PSTP Post-Bac Scholars Program. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.

Dantas G, Helmink BA, Rebeck ON, WallaceMJ, Prusa J, and Kwak S are inventors on a patent application related to the yeast-based ICI delivery system. Dantas G and Kwak S are inventors on another patent related to the use of engineered microbes as therapeutic agents (Publication #: WO/2020/061389, filed 20 Sept. 2019).

Drug bypasses suppressive immune cells to unleash immunotherapy

By recruiting the immune system to combat tumor cells, immunotherapy has improved survival rates, offering hope to millions of cancer patients. However, only about one in five people responds favorably to these treatments.

With a goal of understanding and addressing immunotherapy’s limitations, researchers at Washington University School of Medicine in St. Louis have found that the immune system can be its own worst enemy in the fight against cancer. In a new study in mice, a subset of immune cells – type 1 regulatory T cells, or Tr1 cells – did its normal job of preventing the immune system from overreacting but did so while inadvertently restraining immunotherapy’s cancer-fighting power.

“Tr1 cells were found to be a heretofore unrecognized obstacle to immunotherapy’s effectiveness against cancer,” said senior author Robert D. Schreiber, PhD, the Andrew M. and Jane M. Bursky Distinguished Professor in the Department of Pathology & Immunology, and director of the Bursky Center for Human Immunology & Immunotherapy at Washington University School of Medicine. “By removing or circumventing that barrier in mice, we successfully reenergized the immune system’s cancer-fighting cells and uncovered an opportunity to expand the benefits of immunotherapy for more cancer patients.”

The study is available in Nature. Schreiber is a research member of Siteman Cancer Center, which is based at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis.

Cancer vaccines represent a new approach to personalize cancer immunotherapy. Aimed at the mutant proteins specific to a patient’s tumor, such vaccines induce killer T cells to attack tumor cells while leaving healthy cells unharmed. Schreiber’s group previously showed that more effective vaccines also activate helper T cells, another immune cell type, that recruit and expand additional killer T cells to destroy the tumors. But when they tried to add increased amounts of the helper T cell target to supercharge the vaccine they found they generated a different type of T cell that inhibited rather than promoted tumor rejection.

“We tested the hypothesis that by increasing helper T cell activation we would induce enhanced elimination of the sarcoma tumors in mice,” said first author Hussein Sultan, PhD, an instructor in pathology & immunology. So he injected groups of tumor bearing mice with vaccines that activated killer T cells equally while triggering a different degree of helper T cell activation.

Much to the researchers’ surprise in this latest study, the vaccine meant to hyperactivate helper T cells produced the opposite effect and inhibited tumor rejection.

“We thought that more helper T cell activation would optimize elimination of the sarcoma tumors in mice,” Sultan said. “Instead, we found that vaccines containing high doses of helper T cell targets induced inhibitory Tr1 cells that completely blocked tumor elimination. We know that Tr1 cells normally control an overactive immune system, but this is the first time they have been shown to dampen its fight against cancer.”

Tr1 cells normally put the brakes on the immune system to prevent it from attacking the body’s healthy cells. But their role in cancer has not been seriously explored. Looking through previously published data, the researchers found that tumors from patients who had responded poorly to immunotherapy had more Tr1 cells compared with tumors of patients who had responded well. The number of Tr1 cells also increased in mice as tumors grew bigger, rendering the mice insensitive to immunotherapy.

To bypass the inhibiting cells, the researchers treated the vaccinated mice with a drug that enhances killer T cells’ fighting power. The drug, developed by biotechnology startup Asher Biotherapeutics, carries modifications in the immune-boosting protein called interleukin 2 (IL-2) that specifically revs up killer T cells and reduces the toxicity of unmodified IL-2 treatments. The additional boost from the drug overcame Tr1 cells’ inhibition and rendered the immunotherapy more effective.

“We are committed to personalizing immunotherapy and broadening its effectiveness,” said Schreiber. “Decades of researching basic tumor immunology have expanded our understanding of how to trigger the immune system to achieve the most robust antitumor response. This new study adds to our understanding of how to improve immunotherapy to benefit more people.”

As co-founder of Asher Biotherapeutics – which provided the mouse version of the modified IL-2 drugs – Schreiber is indirectly involved in the company’s clinical trials testing the human version of the drug as a monotherapy in cancer patients. If successful, the drug has the potential to be tested in combination with cancer treatment vaccines.

Device for noninvasive brain biopsies via blood draw moves closer to market approval

A device aimed at enabling neurosurgeons and other physicians to perform noninvasive blood-based biopsies in adults with brain tumors has received Food and Drug Administration (FDA) “Breakthrough Device” designation. The device includes technology from Washington University in St. Louis and developed by Cordance Medical Inc., a medical device company in Mountain View, Calif.

The designation is aimed at providing patients and health-care providers with timely access to novel medical devices by expediting the review process needed to bring technology toward market approval.

The FDA distinction applies to devices that have undergone rigorous review and show exceptional promise of improved treatment or the ability to diagnose life-threatening or debilitating diseases. The technology was co-invented by Eric C. Leuthardt, MD, the Shi Hui Huang Professor of Neurosurgery at Washington University School of Medicine, and by Hong Chen, PhD, an associate professor of biomedical engineering at the university’s McKelvey School of Engineering and of neurosurgery at the School of Medicine.

Washington University recently licensed the technology to Cordance Medical. Leuthardt and Chen serve as advisers and shareholders of Cordance Medical, which is involved in commercializing the technology.

The device — called NeuroAccess — is portable and noninvasive, and it allows physicians to avoid high-risk brain surgery to obtain blood-based liquid biopsies of patients who have known or suspected brain tumors. The device uses sonobiopsy, a technique that targets the blood-brain barrier, a protective, semi-permeable membrane that prevents harmful substances in the blood from contaminating sensitive tissue in the brain. The interaction of ultrasound and microbubbles causes the blood-brain barrier to open temporarily so RNA, DNA and proteins from the brain can diffuse into the blood.

“The sonobiopsy approach is a revolution in brain diagnostics,” said Leuthardt, also a professor of biomedical engineering, of mechanical engineering and of neuroscience. “Just as magnetic resonance imaging (MRI) transformed how we look at the anatomy of the human brain, sonobiopsy will transform how we examine the brain on a molecular level. Essentially, we’re doing a brain biopsy without the high risks of brain surgery.”

The researchers published a study in September, in the journal NPJ Precision Oncology, that found sonobiopsy was feasible and safe for use in people.

“The breakthrough designation is the success of a team that spans numerous disciplines ranging from medicine, engineering, genetics, neuroscience and entrepreneurship to bring this concept from a very basic scientific model to an ongoing clinical trial,” Leuthardt said. “This is a triumph of collaboration.”

Said Chen, also a professor of radiation oncology and of radiology: “Sonobiopsy is poised to open doors to diagnose brain diseases in which surgical biopsies are often not an option. The technology presents new opportunities in the diagnosis of neurodevelopmental, neurodegenerative and psychiatric disorders.”

Leuthardt is the director and Chen is a member of the Division of Neurotechnology in the Department of Neurosurgery, which focuses on multidisciplinary research to create innovative engineered solutions that can be translated to patients with neurologic diseases. Washington University owns a patent on the sonobiopsy technology.


*Originally published by Washington University School of Medicine.

About Washington University School of Medicine

WashU Medicine is a global leader in academic medicine, including biomedical research, patient care and educational programs with 2,800 faculty. Its National Institutes of Health (NIH) research funding portfolio is the third largest among U.S. medical schools, has grown 52% in the last six years, and, together with institutional investment, WashU Medicine commits well over $1 billion annually to basic and clinical research innovation and training. Its faculty practice is consistently within the top five in the country, with more than 1,800 faculty physicians practicing at 65 locations and who are also the medical staffs of Barnes-Jewish and St. Louis Children’s hospitals of BJC HealthCare. WashU Medicine has a storied history in MD/PhD training, recently dedicated $100 million to scholarships and curriculum renewal for its medical students, and is home to top-notch training programs in every medical subspecialty as well as physical therapy, occupational therapy, and audiology and communications sciences.

Medicare approves whole-genome test for blood cancers

Developed at Washington University, ChromoSeq offers a complete picture of genetic errors that guides precision medicine approaches to treatment

A new test for two blood cancers – developed by a team at Washington University School of Medicine in St. Louis – is the first whole-genome sequencing test for cancer to be approved for reimbursement by the Centers for Medicare & Medicaid Services. The test, known as ChromoSeq, advances precision medicine approaches for treating blood cancers by identifying the full suite of genetic changes in a patient’s cancer cells, which provides crucial information that physicians can use to help determine the optimal treatment strategy for individual patients.

Since 2021, ChromoSeq has been used routinely by Washington University oncologists to guide treatment decisions for patients at Siteman Cancer Center with acute myeloid leukemia (AML) or a group of blood cancers called myelodysplastic syndrome (MDS). Siteman is based at Barnes-Jewish Hospital and Washington University. With Medicare approval for the test, physicians nationwide caring for Medicare patients diagnosed with AML or MDS will be able to order the test through Washington University Pathology Services, and Medicare will cover the cost.

“This approval reflects the power and clinical validity of ChromoSeq to assess the full range of genetic mutations responsible for some of the most deadly blood cancers, which can help guide treatment decisions for individual patients,” said Richard Cote, MD, the Edward Mallinckrodt Professor and head of the Department of Pathology & Immunology, which runs the pathology service in collaboration with the clinical sequencing laboratory at WashU Medicine’s McDonnell Genome Institute. “Private insurance companies often follow Medicare’s lead in coverage decisions, so we expect that there will be demand for this test across the country. This approval stands as a testament to the vision of WashU physician-scientists Eric Duncavage, Dave Spencer, Molly Schroeder and their team, who spent years developing and validating this test.”

In recent years, as genome sequencing technology has advanced, costs have dropped dramatically – helping to make Medicare reimbursement possible. The testing will be performed by the McDonnell Genome Institute, which has extensive expertise in genome sequencing and analysis. Scientists at the Genome Institute were the first in the world to demonstrate the validity of whole-genome sequencing in identifying genetic errors responsible for the development and progression of cancer.

The treatment for AML and MDS depends on the cancers’ aggressiveness in individual patients. Aggressive cancers require intensive treatment with chemotherapy drugs and sometimes a stem cell transplant to put the cancer in remission, while less aggressive blood cancers often can be effectively treated with less intensive drug regimens. Treatment decisions typically hinge on the genetic changes exhibited by a patient’s cancer. Standard tests used in a patient’s diagnostic workup are only able to assess some of these changes and provide a limited view of the genetic errors that may be driving the development of a patient’s cancer.

Under the current standard of care, genetic changes are assessed using a combination of three tests: cytogenetics, which reveals chromosomal rearrangements and abnormalities; fluorescence in-situ hybridization, which also identifies chromosomal abnormalities as well as other mutations; and targeted sequencing of specific genes that previously have been linked to AML and MDS.

In 2021, David H. Spencer, MD, PhD, an associate professor of medicine; Eric J. Duncavage, MD, a professor of pathology & immunology; Molly C. Schroeder, PhD, an assistant professor of pathology & immunology; Shelly O’Laughlin, the director of clinical operations at the Genome Technology Access Center at the McDonnell Genome Institute; and Timothy J. Ley, MD, the Lewis T. and Rosalind B. Apple Professor of Medicine, published a groundbreaking paper in The New England Journal of Medicine showing that ChromoSeq is at least as accurate and often better than conventional genetic tests at providing the information necessary for doctors to determine the best treatment.

“All of the information that you can get from the three different tests that doctors now order as standard of care, we can get from ChromoSeq in one test,” said Meagan Jacoby, MD, PhD, an associate professor of medicine. “That can be important because sometimes the other tests don’t produce reliable results, and without that data, we have less confidence in our ability to assess a patient’s risk of aggressive disease. Knowing whether a patient is at low or high risk of aggressive disease is essential for us to know how to treat each patient most appropriately.”

Jacoby leads two ongoing clinical trials to evaluate how the data provided by ChromoSeq compares with standard-of-care testing, and how doctors use ChromoSeq under real-life conditions. Since ChromoSeq gathers data on the whole genome, it can scan for known mutations that are too rare to be included in targeted genetic sequencing tests. Jacoby said that preliminary data from the two ongoing clinical trials suggests that, in comparison to conventional tests, ChromoSeq can generate additional information that could change how individual patients are treated. The full impact of using ChromoSeq won’t be known until the trials are completed.

ChromoSeq also can be quickly updated as more information becomes available about how particular genetic changes contribute to blood cancers.

Study reveals how treatment-resistant prostate cancer provides its own hormonal fuel

A new study in mice, led by researchers at Washington University School of Medicine in St. Louis, explains how prostate cancer senses a drop in testosterone levels due to common anti-hormone therapy and then begins making cholesterol — a necessary precursor to testosterone — to generate its own testosterone to fuel tumor growth. The study also points to a possible drug combination that may stop the cancer from feeding its own growth.

Healthy prostate cells do not produce testosterone, so the research provides long-sought answers to questions about how prostate cancer cells adapt to testosterone-deprivation therapy, a common therapeutic option, by developing an ability to supply their own hormonal fuel. Further, the research reveals that treating these aggressive prostate tumors with inhibitors that block aspects of the hormonal fuel supply chain slows tumor growth in mice. These findings suggest a novel treatment strategy for prostate cancer that has become resistant to the common anti-testosterone therapy abiraterone.

The study appears June 9 in the journal Nature Communications.

The study also may help explain why Black men are at higher risk of developing prostate cancer and tend to develop more aggressive forms of the cancer than white men of European ancestry.

“We’ve known for a long time that androgens, or male hormones such as testosterone, fuel prostate tumors — and we have drugs to treat prostate cancer that block the body’s ability to make testosterone,” said senior author Nupam Mahajan, PhD, a professor of surgery in the Division of Urologic Surgery. “But after about a year, these drugs stop working, and the androgen levels rise again. Where is this androgen coming from? Turns out, prostate cancer cells have learned a new trick; they start producing more cholesterol, which they divert to generate their own androgen. Our study shows how to block this, revealing a possible drug combination that could stop prostate cancer from fueling its own growth.”

Mahajan is also a research member of Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.

The study demonstrated how the prostate cancer cells first detect that androgen levels have dropped. The researchers found that a key protein called SREBF1, when bound to the androgen receptor, acts as an androgen sensor. When androgen levels are low, this protein enters the cancer cell nucleus, recruits an enzyme, GCN5, to modify proteins called histones through a process called acetylation. This epigenetic modification activates many genes important for manufacturing cholesterol and lipids. According to Mahajan, these two molecular events allow the cells to make enormous amounts of cholesterol, a necessary precursor for testosterone.

“The cancer cells essentially load up the tumor with cholesterol and use that cholesterol to churn out more testosterone,” Mahajan said. “That’s the trick. They overload the prostate with cholesterol, and the normal systems for making androgen from cholesterol just work as they typically would, making drugs like abiraterone ineffective.”

Mahajan and his colleagues experimented with two inhibitors that block the molecular events that they found to be responsible for the massive cholesterol manufacturing. They used these inhibitors to treat mice that had prostate tumors that had been sampled from human patients.

One drug is afatinib, an EGFR inhibitor approved by the Food and Drug Administration to treat certain types of lung cancer. The second drug is a GCN5 inhibitor. GCN5 inhibitors have not yet made it into clinical trials, but Mahajan said there is great interest in developing this class of drugs, which could have an effect on gene regulation, cell growth and inflammation. Mice treated with a combination of these two inhibitors showed large reductions in tumor volume compared with mice treated with placebo or the anti-testosterone drug abiraterone alone.

The study also suggests that the cholesterol abundance in aggressive prostate cancer may shed light on racial disparities seen in this tumor type. The researchers found evidence that the lipid profile of prostate cancer in African American men resembles the lipid profile of treatment-resistant prostate cancer identified in this study. In other words, for reasons that remain unclear, African American men with prostate cancer appear to be more prone to having an abundance of cholesterol in their tumors than white men with the same tumor type.

“This is preliminary data, so we need to verify it in larger studies,” Mahajan said. “But our study suggests that this cholesterol profile may play an important role in African American patients with prostate cancer. African American men are at higher risk of prostate cancer, are diagnosed at earlier ages, and now we see that the kinds of cholesterol molecules that are generated in their cancers are similar to what we see in this overactive cholesterol manufacturing pathway. Their cancers are more likely to already be making these lipids, even before beginning anti-testosterone treatment.”

“We are hopeful this study will provide a solid rationale for undertaking a clinical trial of these two inhibitors combined — to block this cholesterol pathway — in patients with treatment-resistant prostate cancer,” Mahajan added.



*Originally published by Washington University School of Medicine.

Red flags indicate risk for early-onset colorectal cancer

Researchers at Washington University School of Medicine in St. Louis have identified four important signs and symptoms that signal an elevated risk of early-onset colorectal cancer. These red flags may be key to earlier detection and diagnosis of early-onset colorectal cancer among younger adults. The number of young adults with colorectal cancer has nearly doubled in recent years.

Studying de-identified health insurance data on more than 5,000 patients with early-onset colorectal cancer — cancer that occurs before a person turns 50 — the researchers found that in the period between three months and two years before diagnosis, abdominal pain, rectal bleeding, diarrhea and iron deficiency anemia each indicate an increased risk in those under age 50. They found that having a single one of the symptoms almost doubled the risk; having two symptoms increased risk by more than 3.5 times; and having three or more boosted the risk by more than 6.5 times.

The study is published May 4 in the Journal of the National Cancer Institute.

“Colorectal cancer is not simply a disease affecting older people; we want younger adults to be aware of and act on these potentially very telling signs and symptoms — particularly because people under 50 are considered to be at low risk, and they don’t receive routine colorectal cancer screening,” said senior investigator Yin Cao, ScD, an associate professor of surgery in the Public Health Sciences Division, and a research member of Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine.

“It’s also crucial to spread awareness among primary care doctors, gastroenterologists and emergency medicine doctors,” Cao said. “To date, many early-onset colorectal cancers are detected in emergency rooms, and there often are significant diagnostic delays with this cancer.”

Cao said two symptoms in particular — rectal bleeding and iron deficiency anemia, a condition in which there are not enough healthy red blood cells to carry oxygen — point to the need for timely endoscopy and follow-up.

In this study, Cao, with first author Cassandra D. L. Fritz, MD, an assistant professor of medicine in the Division of Gastroenterology, and co-first author Ebunoluwa Otegbeye, MD, a general surgery resident, analyzed cases of early-onset colorectal cancer and matched controls using the IBM MarketScan Commercial Database, a big-data tool that provides longitudinal, de-identified information based on health insurance claims data from about 113 million insured adults ages 18 to 64.

“It usually takes about three months to get a diagnosis from the time a person first goes to the doctor with one or more of the red-flag signs and symptoms we’ve identified,” Fritz said. “But in this analysis, we found that some young adults had symptoms for up to two years prior to their diagnoses. That may be part of the reason many of these younger patients had more advanced disease at the time of diagnosis than what we normally see in older people who get screened regularly.”

Individuals born in 1990 have double the risk of colon cancer and four times the risk of rectal cancer compared with young adults born in 1950. That trend has prompted the National Cancer Institute, American Cancer Society, American Gastroenterological Association and other professional societies to prioritize research on identifying risk factors and improving early detection. In 2021, the U.S. Preventive Services Task Force lowered the recommended age for colorectal cancer screening from 50 to 45.

Cao, also an associate professor of medicine, leads a research group focused on identifying risk factors and molecular variations in early-onset colorectal cancer. Her group is among the first to report that obesity, prolonged sitting, metabolic syndrome, diabetes, sugar-sweetened beverages and other risk factors may contribute to the rising incidence of early-onset colorectal cancer.

According to the American Cancer Society, although the death rate from colorectal cancer has been dropping for several decades in older adults due to regular colonoscopies and improved treatment, more younger people are diagnosed with the disease at advanced stages, and many are dying of the disease.

Such a shift suggests urgency in recognizing symptoms as early as possible.

“Since the majority of early-onset colorectal cancer cases have been and will continue to be diagnosed after symptom presentation, it is crucial to recognize these red-flag signs and symptoms promptly and conduct a diagnostic work-up as soon as possible,” Cao said. “By doing so, we can diagnose the disease earlier, which in turn can reduce the need for more aggressive treatment and improve patients’ quality of life and survival rates.”




*Originally published by Washington University School ofMedicine.